Sanofi’s Sarclisa (isatuximab) has been approved by the Medicines and Healthcare product Regulatory Agency (MHRA) as part of a combination treatment for newly diagnosed multiple myeloma (MM).
CT-guided infiltration treatment was well tolerated and was associated with virtually no side effects in this study. Conclusion: CT-guided infiltration of dexamethasone palmitate, particularly in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback